Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 2000

View Archived Issues

CV Therapeutics' CVT-3146 enters phase I testing

IGT Pharma signs agreement with NTB to facilitate merger

Antizol approved in Canada for treatment of ethylene glycol poisoning

NeoTherapeutics expands scope to include cancer therapy; subsidiary established

Inflazyme reports company progress in quarterly shareholder letter

Magnesium sulfate emerges as a potential therapy for stroke

Series of nicotinic acetylcholine receptor ligands claimed by NeuroSearch

Researchers at RCT discover novel compounds for degenerative bone disorders

International patent issued to Sanofi-Synthelabo for new anticoagulants

Novel series of vitronectin receptor antagonists claimed by BASF

NPY antagonists and their use in obesity described by Pfizer

Specific CRF1 ligands designed at Neurogen

Water-soluble antifungal agents from Janssen display potent, broad-spectrum activity

Refractory/relapsed diffuse large B-cell NHL responds well to epratuzumab

Company Profile: Pozen

SB-251353-stimulated neutrophils show enhanced bactericidal activity

Roche and deCODE Genetics identify chromosomal location of osteoporosis gene

Phase I study results reported in San Francisco for MEDI-507 in GVHD

Company Profile: Keryx Biopharmaceuticals

Progen completes patient recruitment for phase Ib trial of PI-88 in cancer

Higher doses of interferon beta-1a offer no additional clinical benefit for MS patients

NaPro BioTherapeutics in-licenses technology for altering genes, sets up genomics division

Antigenics expands pancreatic cancer phase I/II trial following positive data with Oncophage vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...